Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Pharm Res
2008 Aug 01;258:1851-60. doi: 10.1007/s11095-008-9597-0.
Show Gene links
Show Anatomy links
Use of tc-99m mebrofenin as a clinical probe to assess altered hepatobiliary transport: integration of in vitro, pharmacokinetic modeling, and simulation studies.
Ghibellini G
,
Leslie EM
,
Pollack GM
,
Brouwer KL
.
???displayArticle.abstract???
Transport of the hepatobiliary scintigraphy agent Tc-99m mebrofenin (MEB) was characterized and simulation studies were conducted to examine the effects of altered hepatic transport on MEB pharmacokinetics in humans. MEB transport was investigated in Xenopus laevis oocytes expressing OATP1B1 or OATP1B3, and in membrane vesicles prepared from HEK293 cells transfected with MRP2 or MRP3. A pharmacokinetic model was developed based on blood, urine and bile concentration-time profiles obtained in healthy humans, and the effect of changes in hepatic uptake and/or excretion associated with disease states (hyperbilirubinemia and cholestasis) on MEB disposition was simulated. MEB (80 pM) transport by OATP1B1 and OATP1B3 was inhibited by rifampicin (50 microM) to 10% and 4% of control, respectively. MEB (0.4 nM) transport by MRP2 was inhibited to 12% of control by MK571 (50 microM); MRP3-mediated transport was inhibited to 5% of control by estradiol-17-beta-glucuronide (100 microM). A two-compartment model described MEB (2.5 mCi) systemic disposition in humans (systemic clearance = 16.2 +/- 2.7 ml min(-1) kg(-1)); biliary excretion was the predominant route of hepatic elimination (efflux rate constants ratio canalicular/sinusoidal = 3.4 +/- 0.8). Based on simulations, altered hepatic transport markedly influenced MEB systemic and hepatic exposure. MEB may be a useful probe to assess how altered hepatic function at the transport level modulates hepatobiliary drug disposition.
???displayArticle.pubmedLink???
18509604
???displayArticle.pmcLink???PMC2634848 ???displayArticle.link???Pharm Res ???displayArticle.grants???[+]
Araikum,
Hepatobiliary kinetics of technetium-99m-IDA analogs: quantification by linear systems theory.
1996, Pubmed
Araikum,
Hepatobiliary kinetics of technetium-99m-IDA analogs: quantification by linear systems theory.
1996,
Pubmed
Barnes,
Induction of hepatobiliary efflux transporters in acetaminophen-induced acute liver failure cases.
2007,
Pubmed
Bow,
The impact of plasma protein binding on the renal transport of organic anions.
2006,
Pubmed
,
Xenbase
Bujanover,
99mTc-HIDA cholescintigraphy in children with Dubin-Johnson syndrome.
1983,
Pubmed
Chandra,
The complexities of hepatic drug transport: current knowledge and emerging concepts.
2004,
Pubmed
Cui,
Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6.
2001,
Pubmed
Donner,
Up-regulation of basolateral multidrug resistance protein 3 (Mrp3) in cholestatic rat liver.
2001,
Pubmed
Geier,
Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration.
2007,
Pubmed
Gencoglu,
Evaluation of pediatric liver transplant recipients using quantitative hepatobiliary scintigraphy.
2002,
Pubmed
Ghibellini,
A novel method for the determination of biliary clearance in humans.
2004,
Pubmed
Guhlmann,
Noninvasive assessment of hepatobiliary and renal elimination of cysteinyl leukotrienes by positron emission tomography.
1995,
Pubmed
Hagenbuch,
Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties.
2004,
Pubmed
Hendrikse,
In vivo imaging of hepatobiliary transport function mediated by multidrug resistance associated protein and P-glycoprotein.
2004,
Pubmed
Ito,
Mutation of Trp1254 in the multispecific organic anion transporter, multidrug resistance protein 2 (MRP2) (ABCC2), alters substrate specificity and results in loss of methotrexate transport activity.
2001,
Pubmed
Johnson,
Characterization of transport protein expression in multidrug resistance-associated protein (Mrp) 2-deficient rats.
2006,
Pubmed
Kajihara,
A splice mutation in the human canalicular multispecific organic anion transporter gene causes Dubin-Johnson syndrome.
1998,
Pubmed
Kartenbeck,
Absence of the canalicular isoform of the MRP gene-encoded conjugate export pump from the hepatocytes in Dubin-Johnson syndrome.
1996,
Pubmed
Keitel,
A common Dubin-Johnson syndrome mutation impairs protein maturation and transport activity of MRP2 (ABCC2).
2003,
Pubmed
König,
Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance.
1999,
Pubmed
König,
Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane.
1999,
Pubmed
Koruk,
Evaluation of hepatic functions and biliary dynamics in patients with liver cirrhosis by quantitative scintigraphy.
2003,
Pubmed
Krishnamurthy,
Technetium-99m-iminodiacetic acid organic anions: review of biokinetics and clinical application in hepatology.
1989,
Pubmed
Leslie,
Modulation of multidrug resistance protein 1 (MRP1/ABCC1) transport and atpase activities by interaction with dietary flavonoids.
2001,
Pubmed
Okuda,
Studies of the hepatocellular uptake of the hepatobiliary scintiscanning agent 99mTc-DISIDA.
1986,
Pubmed
Oleschuk,
Substitution of Trp1242 of TM17 alters substrate specificity of human multidrug resistance protein 3.
2003,
Pubmed
Paulusma,
A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome.
1997,
Pubmed
Peters,
Bidirectional transport of iminodiacetic organic anion analogues between plasma and hepatocyte.
1998,
Pubmed
Pinós,
A new diagnostic approach to the Dubin-Johnson syndrome.
1990,
Pubmed
Stöckel,
Characterization of the 5'-flanking region of the human multidrug resistance protein 2 (MRP2) gene and its regulation in comparison withthe multidrug resistance protein 3 (MRP3) gene.
2000,
Pubmed
Toh,
Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome.
1999,
Pubmed
Tsujii,
Exon-intron organization of the human multidrug-resistance protein 2 (MRP2) gene mutated in Dubin-Johnson syndrome.
1999,
Pubmed
Vavricka,
Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver.
2002,
Pubmed
,
Xenbase
